All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
During the 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the ALL Hub was pleased to speak with Michael Pulsipher, Children's Hospital Los Angles, California, US. We asked, Which factors influence the need for allogeneic stem cell transplant consolidation in patients treated with chimeric antigen receptor (CAR) T-cells?
Which factors influence the need for allo-SCT consolidation in patients treated with CAR T-cells?
Pulsipher begins by discussing curative CAR T-cell products and key factors to consider in CAR T-cell selection. He goes on to outline risk factors for increased likelihood of failure such as B-cell aplasia or next generation sequencing based measurable residual disease. Finally he highlights his upcoming study (CAR Cure trial) where they will test the feasibility of moving patients to transplant regularly should they fall into the high risk category.
Progress in immunotherapy for hematologic malignancies
Immunotherapy has long been part of the armamentarium of therapies for hematologic malignancies. One of the first applications of immunotherapy was the use of allogeneic stem cell transplantation...
Development of childhood B-ALL, triggering factors, and prospective treatments
Childhood B-cell acute lymphoblastic leukemia (B-ALL), also termed B-cell precursor ALL, is a malignant disease characterized by the rapid expansion of clonal blast cells...
Subscribe to get the best content related to ALL delivered to your inbox